Evotec's Biodefense Win Lands as Horizon Restructuring Takes Center Stage

Evotec began a Phase 1 study of biodefense antibody JST-018, but shares trade at EUR 3.14 after July's 2026 guidance cut and a 19.2% first-half revenue drop.

Evotec has pushed its biodefense candidate JST-018 into human testing, with the German drug developer and its Just – Evotec Biologics subsidiary confirming the launch of a Phase 1 study. The antibody program targets orthopoxviruses and sits inside a U.S. biological defense initiative — a tangible sign that the company's biologics platform continues to deliver even as the broader business faces heavy weather.

The milestone slots into a run of partnership announcements that have done little to lift the stock. Roughly a week before the study news, Evotec unveiled a research collaboration with Plectonic Biotech, pairing Plectonic's LOGIBODY technology with Evotec's BiTco platform to pursue T-cell-engaging approaches against solid tumors. Earlier tie-ups, including a deal with Odyssey Therapeutics, point to the same pattern: external partners keep finding value in Evotec's bispecific antibody toolbox.

A Share Price That Won't Budge

None of it has translated into market momentum. The equity has shed 4.7% since the Plectonic disclosure, extending a stretch in which scientific headlines have been drowned out by deeper concerns about the business. At EUR 3.14, the stock trades barely above its 52-week low of EUR 3.12 — a level touched only recently — and sits more than 50% below the EUR 7.75 peak reached last November. Measured against that high, the decline runs past the halfway mark, while the gap to the yearly top still reads at roughly 61% depending on the reference point.

Short-term technicals offer little comfort either. The shares are changing hands 14% beneath their 50-day moving average, a signal that even traders with a short horizon are keeping their distance.

The Anchor Dragging on Sentiment

The real weight on the valuation traces back to mid-July, when Evotec slashed its 2026 guidance. Revenue expectations were cut from EUR 700–780 million to EUR 570–610 million, while the projected adjusted EBITDA loss ballooned from a range of EUR 0–40 million to EUR 70–105 million. August's half-year report confirmed the grim picture: first-half revenue collapsed 19.2% to EUR 300.1 million, and adjusted EBITDA came in at minus EUR 42.7 million. Nearly two months on, that downgrade still functions as the reference point against which every new announcement gets judged.

What matters now is whether the "Horizon" transformation, announced in March, actually delivers the savings it promised. Evotec intends to shrink its global site footprint to ten locations and strip out around EUR 75 million in costs by the end of 2027, with 20% to 30% of that achieved this year. Restructuring charges of EUR 75 million already landed in the first quarter, and investors are far more focused on whether those efficiencies show up in upcoming quarterly results and steady the free cash flow than on any single collaboration headline.

Two Paths From Here

The bull case rests on execution. If the cost targets are met, adjusted EBITDA could stabilize faster than the market currently prices in. Milestone payments from partners like Plectonic and Odyssey could inject liquidity without Evotec committing its own capital, and the arrival of Claire Hinshelwood as finance chief in May gives the restructuring fresh leadership at the top of the finance function.

The bear case is the mirror image: a shrinking top line colliding with persistent overhaul costs. A near-one-fifth revenue drop in the first half shows the core business is under real pressure, and collaboration news alone hasn't offset that — the price action of recent weeks makes the point. The departure of Camilla Macapili Languille from the supervisory board about a month ago has added to questions about management continuity during a critical stretch. Should "Horizon" savings arrive more slowly than planned, or should further one-off charges surface, the market may decide the already-reduced guidance wasn't conservative enough.

What to Watch

A floor near current levels is plausible so long as the restructuring stays on schedule and the partnership pipeline keeps drawing new names. But if revenue keeps sliding or the Horizon effects slip, the July downgrade could come back under scrutiny — and with it, more downward pressure on the shares. Third-quarter figures are the next real test, the moment when it becomes clear whether the cost measures are actually reaching the bottom line. Until then, Evotec remains a stock where scientific progress and structural doubt are locked in a tug of war.